VCTC Proudly Participates in Ground-breaking Cancer Research Featured in The Times
VCTC Proudly Participates in Groundbreaking Cancer Research Featured in The Times
VCTC is pleased to announce its active participation in an innovative clinical trial that was recently highlighted in The Times newspaper. The trial, led by British biotech company Artelo Biosciences, aims to improve the quality of life for cancer patients by addressing significant weight and muscle loss, a common challenge during treatment.
The article in The Times showcased the potential impact of the trial and described how the investigational drug mimics a cannabis molecule, designed to act on cannabinoid receptors to stimulate appetite and weight gain without psychoactive effects. If successful, this treatment could be one of the first of its kind, potentially available as early as 2028.
“We are excited to be part of such a pioneering study,” said Dan Henley of VCTC. “This research aligns with our commitment to advancing patient care and providing new, effective solutions for cancer patients facing significant challenges during their treatment.”
The investigational drug has been developed in tablet form and could address the needs of 60-80% of cancer patients who experience weight and muscle loss, which correlates strongly with treatment outcomes. VCTC’s involvement in this trial highlights its dedication to contributing to impactful research that could change the standard of care for cancer patients.
Artelo Biosciences’ Chief Scientific Officer, Dr Andy Yates, emphasized in the Times article: “Sadly, there are not very many treatment options available for those suffering weight loss, so we hope that our drug will help transform that by giving people their appetite back, and more importantly, help them gain weight and an improved quality of life.”
About VCTC
VCTC is an industry-leading, UK-based provider of clinical trial services, experts in both delivering virtual clinical trials and enhancing traditional trial models. Founded in 2021 by Dr. Helen Shaw and Dan Henley, VCTC’s mission is to make clinical research accessible and meaningful for anyone, anywhere. Through flexible site options for clinical research that empower participants and prioritise the participant experience, VCTC ensures patient voices are valued, and research outcomes are accelerated.
About Artelo Biosciences
Artelo Biosciences is a pioneering biotech company focused on developing novel therapeutics that harness the potential of cannabinoid-based medicine for the benefit of patients worldwide.
For more information about the clinical trial or to inquire about participation, please get in touch with us.
